New study reveals that most americans cannot identify the symptoms of depression .

 New study reveals that most Americans cannot identify the symptoms of depression .

Americans and depression

SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a pacesetter in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight® mental state Monitor.

The survey found that almost one in two adults are very confident they might recognize if a beloved is affected by depression. However, when given an inventory of possible symptoms, just one in seven could correctly identify all of the possible symptoms.


“The initiative to recovery from depression is recognizing the symptoms of depression in yourself or someone on the brink of you,” said Mark Pollack, M.D., a chief medic for psychological state at Myriad Genetics. “If you recognize depression symptoms in yourself or others, it’s important to hunt treatment with a knowledgeable healthcare provider.”

However, recognizing depression then offering or seeking help is not always easy. While many might want to assist, the poll found nearly half of respondents are not sure they completely “get” what people diagnosed with depression are browsing.

Leslie, whose husband, Art, suffered from major clinical depression most of his life, agrees that it is hard to understand what an individual with depression is experiencing.

“Art was very unpredictable and irrational. He was extremely moody,” Leslie said. “I would click from work and would not know what I used to be walking into. Would he be angry? Would he be lethargic and unable to urge off the couch? Would he be irritable? Would he even be there?”

This lack of understanding also applies to those that experience depression themselves. The GeneSight psychological state Monitor found 15 per cent of those with depression admit that even they do not always get what others are browsing – a sign that the disorder does not look or feel equivalent to everyone who lives with depression.


Although each person’s experience with depression is exclusive, there are a variety of common symptoms.

About eight in 10 people believe symptoms of depression are emotional (88 per cent), mental (83 per cent) and behavioural (80 per cent), however, only about six in 10 (63 per cent) of yank adults recognize that physical symptoms were related to depression, consistent with the poll. Depression can manifest in physical ways such as:

o Headaches and pain digestive issues

o Fatigue

o Sleeping issues

o Changes in appetite or weight

“Many patients have common complaints like fatigue or weight gain, and after a comprehensive assessment, I’ve determined that depression was at the basis of their problems,” said Robin Miller, Internist, MD, MHS, owner of Triune Integrative Medicine in Medford, Ore. “That is why people need to understand this disorder and understand its symptoms. Quicker diagnosis can lead to treatment.”

For a far better understanding of potential symptoms of depression and to experience how hard it is often to travel about lifestyle while living with depression, visit For more information on how genetic testing can help inform clinicians on depression treatment, please visit

The GeneSight psychological state Monitor may be a nationwide survey of United States of America adults conducted by ACUPOLL Precision Research, Inc. in March 2021 among a statistically stratified sample of adults age 18+, including a stratified sample diagnosed with depression. The margin of error in survey results for the entire base population at a 95 per cent confidence interval is 3 per cent.

The GeneSight Psychotropic test from Myriad Genetics is that the category-leading pharmacogenomic test for 61 medications commonly prescribed for depression, anxiety, Attention deficit hyperactivity disorder (ADHD), and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patient’s genes may impact how they metabolize or answer certain psychiatric medications. It has been given to quite 1.5 million patients by tens of thousands of clinicians to supply genetic information that is unique to every patient. The GeneSight test supplements other information considered by a clinician as a part of a comprehensive medical assessment. Learn more at


Myriad Genetics could also be a number one genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the danger of developing the disease, assess the danger of disease progression, and guide treatment decisions across medical specialities where critical genetic insights can significantly improve patient care and lower health care costs. For more information, visit the Company’s website:

Myriad, the Myriad logo, BART, BRAC Analysis, Solaris, Colaris AP, My risk, Myriad My risk, My risk Hereditary Cancer, My choice, My plan, BRACA analysis CDx, Tumour BRACA analysis CDx, my choice CDx, Vectra, Endo Predict, Prequel, Foresight, GeneSight, Risk score and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly-owned subsidiaries within us and foreign countries.


Previous Post Next Post